CA
NZ
UK
AU
IND
US
Zentalis Pharmaceuticals shares rose on Monday after Leerink Partners upgraded the cancer-drug developer to Outperform and doubled its price target ahead of key data later this month.
Aclaris Therapeutics (NASDAQ:ACRS) is advancing a diversified pipeline of immuno-inflammatory product candidates, including bosakitug, an anti-TSLP monoclonal antibody in Phase 2 development for conditions such as atopic dermatitis and asthma, zunsemetinib, a dual ITK and JAK3 inhibitor with Phase 2a data presented at a …
Aethlon Medical's (NASDAQ:AEMD) July 2026 follow-on offering, which raised 4 million dollars in gross proceeds through units priced at roughly 71 cents each, included a 90-day lock-up restricting directors and officers from selling their holdings. That lock-up period's scheduled end date falls in early …
BioAge Labs (NASDAQ:BIOA), a clinical-stage biopharmaceutical company, announced dosing of the first participant in QUELL-DME, a controlled study evaluating oral BGE-102 in adults with diabetic macular edema. The trial assigns participants to different treatment approaches: one group receives anti-VEGF therapy with an oral placebo, …
GRAIL (NASDAQ:GRAL) has completed its premarket approval submission to the FDA for Galleri, its multi-cancer early detection test, building on positive topline results already disclosed from the registrational NHS-Galleri trial, a randomized controlled study conducted within England's National Health Service, and from the PATHFINDER …
Lumexa Imaging Holdings (NASDAQ:LMRI) has drawn initiating coverage with Buy or Strong Buy ratings from a wide roster of major banks, including Jefferies, Wells Fargo, Raymond James, William Blair, Leerink and Barclays, several citing the company's strong local market positions and the pace of …
On October 5, 2026 at 7:00 a.m. ET, Alector announced an exclusive global license giving Genentech, a member of the Roche Group, rights to AL050, a brain-penetrant enzyme replacement therapy for Parkinson's disease built on the Alector Brain Carrier delivery platform. The terms are …
● No confirmed company-specific release was identified for the session.
● Praxis Precision Medicines (PRAX) shares fell 4.04% to close at $283.56 on Monday, October 5, 2026.
● No confirmed company-specific news was identified for the session.
Please wait processing your request...